Protecting Our Children from the CDC ActThis bill prohibits the inclusion of any COVID-19 vaccine on the child and adolescent immunization schedule (which lists the vaccines recommended by the Advisory Committee on Immunization Practices for those populations) unless all clinical data related to the safety and efficacy of the vaccine is published on the website of the Centers for Disease Control and Prevention.
If enacted, HB 87 would require the Secretary of Health and Human Services to disclose comprehensive safety and efficacy data before any COVID-19 vaccine can be included in immunization recommendations for children and adolescents. Furthermore, it mandates the removal of any COVID-19 vaccine already on the immunization schedule at the time of the bill's enactment, effectively pausing its administration until data is publicly available.
House Bill 87, titled the 'Protecting Our Children from the CDC Act', aims to amend the Public Health Service Act to impose restrictions on the inclusion of COVID-19 vaccines in the child and adolescent immunization schedule. The bill stipulates that no COVID-19 vaccine can be added to this schedule unless all relevant clinical data regarding its safety and efficacy is published on the CDC's public website. This effort is framed as a move towards greater transparency regarding the risks and benefits of such vaccines, creating a mechanism for public access to critical health information before regulatory decisions are made.
The bill has generated significant debate among lawmakers and public health advocates. Proponents argue that the legislation will enhance public trust in vaccines by ensuring the availability of detailed safety information. They believe it serves to protect children's health by promoting informed parental decisions regarding immunizations. Conversely, critics contend that the bill could unnecessarily delay vaccinations, adversely affecting community immunity and public health efforts against COVID-19. There are concerns that the requirement for extensive data publication may create barriers to timely vaccine updates needed to respond to emerging infectious diseases.